GoKawiilReport urges faster use of whole genome sequencing to cut rare disease diagnosis delays
A commentary argues that healthcare systems should stop delaying whole genome sequencing for certain patients, saying rare disease diagnoses often take years to reach. It contends the cost of that delay should be counted not just in time but in dollars, clinical capacity, and missed chances for better treatment.
GoKawiil's interpretation of the reporting above, not reported fact.
The piece suggests that framing diagnostic delay as a financial and operational problem, not just a patient hardship, could push hospitals and payers to prioritize sequencing earlier in care pathways. This reframing may be intended to build the case for broader insurance coverage and faster adoption of genomic testing, though the article does not specify which systems or costs are involved.
- Commentary calls for faster whole genome sequencing adoption in rare disease care
- Argues diagnostic delay carries financial and capacity costs beyond patient time lost
- Frames genomic testing speed as a healthcare system efficiency issue, not just a clinical one
Source: fastcompany.com, 2026-11-06
Published there as: “Why diagnostic delays cost more than time”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.